Share on LinkedInShare on LinkedIn

ARTICLE · 03 JUNE 2024

High Stakes: HHS Shakes Things Up On Marijuana Scheduling And DEA Abides

Akin
Akin
Contributor
Akin

Akin

Akin is a global law firm with more than 1,100 lawyers and advisors who pride themselves on...

View firm profile
Explore more from Akin

On May 16th, the U.S. Drug Enforcement Administration issued a Notice of Proposed Rulemaking (NPRM) to initiate the rescheduling of marijuana from a Schedule I to a Schedule III drug.

United StatesCannabis & Hemp

On May 16th, the U.S. Drug Enforcement Administration (DEA) issued a Notice of Proposed Rulemaking (NPRM) to initiate the rescheduling of marijuana from a Schedule I to a Schedule III drug.1The NPRM, which was published in the Federal Register on May 21st, is the first step of a formal rulemaking process required by the Controlled Substances Act (CSA) for rescheduling a controlled substance. This process, as detailed below, will likely include a public hearing before any final rule is published. Should the rescheduling be finalized as proposed, it would present a significant change for those entities in the marijuana industry, including those seeking to conduct medical research using marijuana and its derivatives.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from